Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05851430 · ClinicalTrials.gov registry record

Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry

A clinical trial of Soft Tissue Lesion, sponsored by Galvanize Therapeutics.

Recruiting
Registry status
1,000
Enrollment target
8
Study locations

NCT05851430 is a study of Soft Tissue Lesion that is actively recruiting participants, run by Galvanize Therapeutics. The registered enrollment target is 1,000 participants. The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05851430, a study of Soft Tissue Lesion, is actively recruiting participants, sponsored by Galvanize Therapeutics.

RECRUITING
Registry status
1,000 participants
Enrollment target
8
Study locations

Study Summary

The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo the PEF procedure and be followed per institutional standard of care.

Conditions Studied

Interventions

  • DEVICE PEF ablation

Study Locations (8)

Texas

  • UT Southwestern Medical Center - Dallas
  • University of Texas-Tyler - Tyler

California

  • Eisenhower Medical Center - Rancho Mirage

Florida

  • NCH Baker - Naples

New York

  • New York Presbyterian Langone Health - New York

North Carolina

  • Duke University Hospital - Durham

Pennsylvania

  • Lankenau Institute for Medical Research (LIMR) - Wynnewood

South Carolina

  • AnMed Health - Anderson

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-06-23
Est. Completion 2028-12-31

Sponsor

Galvanize Therapeutics

3 total trials

What the Registry Record Tells You About NCT05851430

The ClinicalTrials.gov registry entry for NCT05851430 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galvanize Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Soft Tissue Lesion appearing as the primary indexed condition, and to 1 intervention - of which PEF ablation is the first listed.

NCT05851430 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT05851430 about?

NCT05851430 is a clinical study titled "Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry". The goal of this observational registry is to assess the use and performance of Galvanize PEF technology in a real-world setting. The main questions it aims to answer are: * PEF utilization and performance * Monitor safety outcomes and inform future generation devices. Participants will undergo th...

What is the current status of trial NCT05851430?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-06-23. Estimated completion is 2028-12-31.

What conditions does trial NCT05851430 study?

This clinical trial studies the following conditions: Soft Tissue Lesion.

What interventions are being tested in trial NCT05851430?

The interventions under investigation include: PEF ablation (DEVICE).

Who is sponsoring clinical trial NCT05851430?

This trial is sponsored by Galvanize Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05851430 being conducted?

This trial has 8 study locations across California, Florida, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Soft Tissue Lesion

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.